Immune Related Adverse Events

Indications for the use of checkpoint inhibitors are ever expanding. However, even as these drugs have helped patients with cancer live longer, the emergence of various immune related adverse events limits their full potential in many.

I recently had the pleasure of attending a symposium at the Cleveland Clinic that featured an outstanding review of immune-related adverse events, and I was reminded of how far we have come in the decade since I first became involved in the evolution of this disease class.

In this episode, host Shikha Jain, MD, speaks with Kerry Reynolds, MD, about immunotherapy-related adverse events, creating educational resources on immunotherapy management and more.

CHICAGO — Post-hoc analyses of the JAVELIN Bladder 100 trial confirmed the acceptable long-term safety of avelumab first-line maintenance for advanced urothelial carcinoma, according to a presentation at ASCO Annual Meeting.

Cutaneous immune-related adverse events are associated with increased survival rates among immune checkpoint inhibitor recipients, particularly in patients with melanoma, according to a study.

Although oncologists take the lead in cancer management with immunotherapies, rheumatologist input is essential to managing the ensuing immune-related adverse events, which pose challenges to coordinated patient care.

Patients with AKI may continue treatment with immune checkpoint inhibitors, even if they have experienced immune checkpoint inhibitor-AKI, according to data published in the Journal for ImmunoTherapy of Cancer.

Female patients with melanoma on immune checkpoint inhibitor therapy exhibited higher rates of dermatologic adverse events compared with male patients, according to a study presented at AAD VMX 2021.

Cutaneous immune-related adverse events are an early sign of immune-mediated toxic events, and dermatologists can play a role in screening for more severe events, according to a study.